Truist Financial Corp Has $4.59 Million Stock Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Truist Financial Corp lifted its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 3.4% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 64,024 shares of the biopharmaceutical company’s stock after acquiring an additional 2,134 shares during the period. Truist Financial Corp owned approximately 0.07% of Intra-Cellular Therapies worth $4,585,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Signaturefd LLC grew its holdings in shares of Intra-Cellular Therapies by 85.7% during the 4th quarter. Signaturefd LLC now owns 518 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 239 shares in the last quarter. Neo Ivy Capital Management acquired a new stake in Intra-Cellular Therapies during the third quarter worth about $45,000. CI Investments Inc. grew its stake in Intra-Cellular Therapies by 1,191.6% during the third quarter. CI Investments Inc. now owns 1,692 shares of the biopharmaceutical company’s stock worth $88,000 after buying an additional 1,561 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Intra-Cellular Therapies by 95.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,465 shares of the biopharmaceutical company’s stock valued at $128,000 after buying an additional 1,207 shares during the period. Finally, Covestor Ltd raised its position in shares of Intra-Cellular Therapies by 64.9% in the 3rd quarter. Covestor Ltd now owns 2,518 shares of the biopharmaceutical company’s stock valued at $131,000 after buying an additional 991 shares in the last quarter. 92.33% of the stock is owned by institutional investors.

Intra-Cellular Therapies Stock Down 2.2 %

Shares of NASDAQ ITCI opened at $68.80 on Monday. The firm has a market cap of $6.66 billion, a PE ratio of -47.12 and a beta of 1.01. The company’s fifty day simple moving average is $69.16 and its 200 day simple moving average is $65.56. Intra-Cellular Therapies, Inc. has a 12-month low of $45.50 and a 12-month high of $84.89.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings data on Thursday, February 22nd. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.14. Intra-Cellular Therapies had a negative net margin of 30.08% and a negative return on equity of 23.02%. The firm had revenue of $132.10 million for the quarter, compared to analyst estimates of $135.97 million. During the same quarter in the prior year, the business earned ($0.45) earnings per share. The business’s quarterly revenue was up 50.3% compared to the same quarter last year. On average, equities analysts predict that Intra-Cellular Therapies, Inc. will post -0.59 earnings per share for the current year.

Insiders Place Their Bets

In related news, CFO Lawrence J. Hineline sold 13,337 shares of the stock in a transaction on Monday, February 26th. The stock was sold at an average price of $69.43, for a total value of $925,987.91. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, CFO Lawrence J. Hineline sold 13,337 shares of the business’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $69.43, for a total transaction of $925,987.91. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Sharon Mates sold 22,590 shares of the company’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $69.79, for a total transaction of $1,576,556.10. Following the completion of the sale, the chief executive officer now owns 1,050,309 shares in the company, valued at approximately $73,301,065.11. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 168,487 shares of company stock worth $11,364,950. Corporate insiders own 3.40% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Bank of America raised their target price on Intra-Cellular Therapies from $82.00 to $91.00 and gave the company a “buy” rating in a report on Wednesday, April 17th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $120.00 price objective on shares of Intra-Cellular Therapies in a report on Wednesday, April 24th. The Goldman Sachs Group upped their price target on shares of Intra-Cellular Therapies from $67.00 to $77.00 and gave the company a “neutral” rating in a research report on Wednesday, April 17th. TD Cowen raised their price target on shares of Intra-Cellular Therapies from $80.00 to $90.00 and gave the company a “buy” rating in a research note on Wednesday, April 17th. Finally, Mizuho boosted their price objective on shares of Intra-Cellular Therapies from $82.00 to $96.00 and gave the stock a “buy” rating in a research note on Monday, April 22nd. Two equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $90.17.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.